Identification

Name
Empagliflozin
Accession Number
DB09038
Type
Small Molecule
Groups
Approved
Description

Empagliflozin is a sodium glucose co-transporter-2 (SGLT-2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes. SGLT2 co-transporters are responsible for reabsorption of glucose from the glomerular filtrate in the kidney. The glucuretic effect resulting from SGLT2 inhibition reduces renal absorption and lowers the renal threshold for glucose, therefore resulting in increased glucose excretion. Additionally, it contributes to reduced hyperglycaemia and also assists weight loss and blood pressure reduction.

Structure
Thumb
Synonyms
  • (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol
  • 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene
  • Empagliflozina
External IDs
BI 10773 / BI-10773 / BI10773
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
JardianceTablet, film coated25 mg/1OralCardinal Health2014-08-01Not applicableUs
JardianceTablet10 mgOralBoehringer Ingelheim (Canada) Ltd Ltee2015-08-11Not applicableCanada
JardianceTablet, film coated25 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.2014-08-01Not applicableUs
JardianceTablet, film coated10 mg/1OralCardinal Health2014-08-01Not applicableUs
JardianceTablet, film coated10 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.2014-08-01Not applicableUs00597 0152 90 nlmimage10 8d40c686
JardianceTablet25 mgOralBoehringer Ingelheim (Canada) Ltd Ltee2015-08-11Not applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
GlyxambiEmpagliflozin (10 mg/1) + Linagliptin (5 mg/1)Tablet, film coatedOralBoehringer Ingelheim Pharmaceuticals, Inc.2015-01-30Not applicableUs0597 018220180913 8702 q7fevz
GlyxambiEmpagliflozin (25 mg) + Linagliptin (5 mg)TabletOralBoehringer Ingelheim (Canada) Ltd Ltee2016-12-21Not applicableCanada
GlyxambiEmpagliflozin (25 mg/1) + Linagliptin (5 mg/1)Tablet, film coatedOralBoehringer Ingelheim Pharmaceuticals, Inc.2015-01-30Not applicableUs
GlyxambiEmpagliflozin (10 mg) + Linagliptin (5 mg)TabletOralBoehringer Ingelheim (Canada) Ltd Ltee2016-12-21Not applicableCanada
SynjardyEmpagliflozin (5 mg) + Metformin Hydrochloride (850 mg)TabletOralBoehringer Ingelheim (Canada) Ltd Ltee2016-08-03Not applicableCanada
SynjardyEmpagliflozin (12.5 mg/1) + Metformin Hydrochloride (500 mg/1)TabletOralBoehringer Ingelheim Pharmaceuticals, Inc.2015-08-26Not applicableUs
SynjardyEmpagliflozin (5 mg) + Metformin Hydrochloride (1000 mg)TabletOralBoehringer Ingelheim (Canada) Ltd Ltee2016-08-03Not applicableCanada
SynjardyEmpagliflozin (12.5 mg) + Metformin Hydrochloride (1000 mg)TabletOralBoehringer Ingelheim (Canada) Ltd Ltee2016-08-03Not applicableCanada
SynjardyEmpagliflozin (5 mg) + Metformin Hydrochloride (500 mg)TabletOralBoehringer Ingelheim (Canada) Ltd Ltee2016-08-03Not applicableCanada
SynjardyEmpagliflozin (5 mg/1) + Metformin Hydrochloride (1000 mg/1)TabletOralBoehringer Ingelheim Pharmaceuticals, Inc.2015-08-26Not applicableUs
Categories
UNII
HDC1R2M35U
CAS number
864070-44-0
Weight
Average: 450.91
Monoisotopic: 450.1445309
Chemical Formula
C23H27ClO7
InChI Key
OBWASQILIWPZMG-QZMOQZSNSA-N
InChI
InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1
IUPAC Name
(2S,3R,4R,5S,6R)-2-[4-chloro-3-({4-[(3S)-oxolan-3-yloxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
SMILES
[H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1

Pharmacology

Indication

Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes.

Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action

Empagliflozin is a sodium glucose co-transporter-2 (SGLT-2) inhibitor. SGLT2 co-transporters are responsible for reabsorption of glucose from the glomerular filtrate in the kidney. The glucuretic effect resulting from SGLT2 inhibition reduces renal absorption and lowers the renal threshold for glucose, resulting in increased glucose excretion. Additionally, it contributes to reduced hyperglycaemia, assists weight loss, and reduces blood pressure.

TargetActionsOrganism
USodium/glucose cotransporter 2
antagonist
inhibitor
Human
Absorption

Following oral administration, peak plasma concentrations were reached at 1.5 hours post-dose and then declined in a biphasic manner with a rapid distribution phase and a relatively slow terminal phase. Administration following a high-fat and high-calorie meal results in a slightly lower exposure with AUC decreasing by approximately 16% and Cmax decreasing by approximately 37% compared to fasted condition.

Volume of distribution

73.8 L

Protein binding

Plasma protein binding was found to be 86.2%

Metabolism

In vitro studies suggest that empaglifozin is primarily metabolized by glucuronidation by 5'-diphospho-glucuronosyltransferases UG2B7, UGT1A3, UGT1A8, and UGT1A9. The most abundant metabolites are three glucuronide metabolites: 2-O-, 3-O-, and 6-O-glucuronide. Empagliflozin does not inhibit, inactivate, or induce CYP450 isoforms. It is a substrate for p-glycoprotein (p-gp), however in vitro studies suggest that it is unlikely to cause interactions with drugs that are p-gp substrates.

Route of elimination

After oral administration, empaglifozin was 41.2% eliminated in feces and 54.4% eliminated in urine.

Half life

Terminal elimination half life was found to be 12.4 h based on population pharmacokinetic analysis.

Clearance

Apparent oral clearance was found to be 10.6 L/h based on population pharmacokinetic analysis.

Toxicity

The most commonly reported adverse effects for empaglifozin were urinary tract infections, female genital mycotic infections, and dyslipidemia. Because empagliflozin causes osmotic diuresis adverse reactions related to volume depletion were also reported (decreased systolic blood pressure, dehydration, hypotension, orthostatic hypotension, hypovolemia, and syncope). Impaired renal function and hypoglycemia were also reported.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2,4-thiazolidinedioneEmpagliflozin may increase the hypoglycemic activities of 2,4-thiazolidinedione.
5-(2-methylpiperazine-1-sulfonyl)isoquinolineThe therapeutic efficacy of Empagliflozin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline.
AbacavirAbacavir may decrease the excretion rate of Empagliflozin which could result in a higher serum level.
AcarboseEmpagliflozin may increase the hypoglycemic activities of Acarbose.
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Empagliflozin.
AceclofenacAceclofenac may decrease the excretion rate of Empagliflozin which could result in a higher serum level.
AcemetacinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Acemetacin.
AcetaminophenAcetaminophen may decrease the excretion rate of Empagliflozin which could result in a higher serum level.
AcetazolamideThe therapeutic efficacy of Empagliflozin can be increased when used in combination with Acetazolamide.
AcetohexamideEmpagliflozin may increase the hypoglycemic activities of Acetohexamide.
Food Interactions
Not Available

References

Synthesis Reference

Wang XJ, Zhang L, Byrne D, Nummy L, Weber D, Krishnamurthy D, Yee N, Senanayake CH: Efficient synthesis of Empagliflozin, an inhibitor of SGLT-2, utilizing an AlCl3-promoted silane reduction of a beta-glycopyranoside. Org Lett. 2014 Aug 15;16(16):4090-3. doi: 10.1021/ol501755h. Epub 2014 Jul 25. Pubmed

General References
  1. Scheen AJ: Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. Clin Pharmacokinet. 2015 Jul;54(7):691-708. doi: 10.1007/s40262-015-0264-4. [PubMed:25805666]
  2. Gangadharan Komala M, Mather A: Empagliflozin for the treatment of Type 2 diabetes. Expert Rev Clin Pharmacol. 2014 May;7(3):271-9. doi: 10.1586/17512433.2014.908703. Epub 2014 Apr 9. [PubMed:24716752]
  3. Lamos EM, Younk LM, Davis SN: Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opin Investig Drugs. 2014 Jun;23(6):875-82. doi: 10.1517/13543784.2014.909407. Epub 2014 Apr 19. [PubMed:24746173]
  4. Liakos A, Karagiannis T, Athanasiadou E, Sarigianni M, Mainou M, Papatheodorou K, Bekiari E, Tsapas A: Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014 Oct;16(10):984-93. doi: 10.1111/dom.12307. Epub 2014 May 28. [PubMed:24766495]
  5. Haring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, Woerle HJ: Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014 Jun;37(6):1650-9. doi: 10.2337/dc13-2105. Epub 2014 Apr 10. [PubMed:24722494]
  6. Neumiller JJ: Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Drugs Context. 2014 Jun 11;3:212262. doi: 10.7573/dic.212262. eCollection 2014. [PubMed:24991224]
  7. Bogdanffy MS, Stachlewitz RF, van Tongeren S, Knight B, Sharp DE, Ku W, Hart SE, Blanchard K: Nonclinical safety of the sodium-glucose cotransporter 2 inhibitor empagliflozin. Int J Toxicol. 2014 Nov-Dec;33(6):436-49. doi: 10.1177/1091581814551648. Epub 2014 Sep 26. [PubMed:25260362]
  8. Authors unspecified: Empagliflozin (Jardiance) for diabetes. Med Lett Drugs Ther. 2014 Oct 13;56(1453):99-100. [PubMed:25296258]
  9. Jahagirdar V, Barnett AH: Empagliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2014 Nov;15(16):2429-41. doi: 10.1517/14656566.2014.966078. [PubMed:25301180]
External Links
KEGG Drug
D10459
PubChem Compound
11949646
PubChem Substance
310264986
ChemSpider
10123957
BindingDB
150162
ChEBI
82720
ChEMBL
CHEMBL2107830
PharmGKB
PA166163327
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Empagliflozin
ATC Codes
A10BD19 — Linagliptin and empagliflozinA10BX12 — EmpagliflozinA10BD20 — Metformin and empagliflozin
AHFS Codes
  • 68:20.18 — Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
FDA label
Download (604 KB)
MSDS
Download (99 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentHealthy Volunteers1
1Active Not RecruitingTreatmentType 2 Diabetes Mellitus1
1CompletedNot AvailableHealthy Volunteers1
1CompletedBasic ScienceDiabetes Mellitus (DM)1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentHealthy Volunteers24
1CompletedTreatmentHealthy Volunteers / Hepatic Insufficiency1
1CompletedTreatmentType 2 Diabetes Mellitus7
1Not Yet RecruitingTreatmentType 2 Diabetes Mellitus1
2CompletedTreatmentDiabetes Type 2 With Heart Failure1
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 13
2CompletedTreatmentHealthy Volunteers / Type 2 Diabetes Mellitus1
2CompletedTreatmentType 2 Diabetes Mellitus8
2Enrolling by InvitationTreatmentHeart Failure, Unspecified / Type 2 Diabetes Mellitus1
2RecruitingBasic ScienceBody Weights / Pre-Diabetic1
2RecruitingBasic ScienceRenal Dysfunction1
2RecruitingTreatmentAcute Heart Failure (AHF) / Heart Failure; With Decompensation / Heart Failure,Congestive1
2RecruitingTreatmentAcute Heart Failure (AHF) / Type 2 Diabetes Mellitus1
2RecruitingTreatmentBMI >30 kg/m2 / Diabetes, Diabetes Mellitus Type 1 / Type 2 Diabetes Mellitus1
2RecruitingTreatmentChronic Heart Failure (CHF)1
2RecruitingTreatmentChronic Kidney Disease stage3 / Chronic Kidney Disease stage4 / Diabetic Kidney Disease / Type 2 Diabetes Mellitus1
2RecruitingTreatmentDiabetes Mellitus (DM)1
2RecruitingTreatmentEnd Stage Renal Disease (ESRD)1
2RecruitingTreatmentHeart Failure With Reduced Ejection Fraction (HFrEF)1
2RecruitingTreatmentPosttransplant Diabetes Mellitus1
2RecruitingTreatmentType 2 Diabetes Mellitus2
2, 3CompletedHealth Services ResearchPolycystic Ovaries Syndrome1
2, 3Enrolling by InvitationTreatmentSIADH1
2, 3RecruitingTreatmentHyponatremias / SIAD - Syndrome of Inappropriate Antidiuresis1
3CompletedTreatmentBMI >30 kg/m2 / Type 2 Diabetes Mellitus1
3CompletedTreatmentDiabetes Mellitus (DM) / Type 2 Diabetes Mellitus1
3CompletedTreatmentDiabetes, Diabetes Mellitus Type 12
3CompletedTreatmentHigh Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus2
3CompletedTreatmentImpaired Renal Function / Type 2 Diabetes Mellitus1
3CompletedTreatmentType 2 Diabetes Mellitus15
3Not Yet RecruitingPreventionGestational Diabetes Mellitus (GDM)1
3Not Yet RecruitingTreatmentChronic Kidney Disease (CKD)1
3RecruitingTreatmentAcute Myocardial Infarction (AMI)1
3RecruitingTreatmentDiabetic Kidney Disease / Type 2 Diabetes Mellitus1
3RecruitingTreatmentHeart Failure, Unspecified5
3RecruitingTreatmentType 2 Diabetes Mellitus3
3RecruitingTreatmentType2 Diabetes Mellitus1
3TerminatedTreatmentType 2 Diabetes Mellitus1
3Unknown StatusTreatmentType 2 Diabetes Mellitus1
3WithdrawnTreatmentType 2 Diabetes Mellitus1
4Active Not RecruitingDiagnosticCardiovascular Disease (CVD) / Diabetes Mellitus (DM)1
4Active Not RecruitingPreventionObesity, Visceral1
4Active Not RecruitingTreatmentDiabetes Mellitus (DM) / Impaired Renal Function / Safety Issues1
4Active Not RecruitingTreatmentHeart Failure, Unspecified / Type 2 Diabetes Mellitus1
4Active Not RecruitingTreatmentType 2 Diabetes Mellitus1
4CompletedBasic ScienceType 2 Diabetes Mellitus1
4CompletedTreatmentType 2 Diabetes Mellitus2
4Not Yet RecruitingPreventionHigh Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
4Not Yet RecruitingTreatmentHeart Failure, Unspecified1
4Not Yet RecruitingTreatmentNAFLD - Nonalcoholic Fatty Liver Disease / Type2 Diabetes1
4Not Yet RecruitingTreatmentType2 Diabetes Mellitus1
4RecruitingTreatmentCardiovascular Disease (CVD)1
4RecruitingTreatmentCoronary Heart Disease (CHD) / Diabetes Mellitus (DM)1
4RecruitingTreatmentDiabetes Complications / Diabetes, Diabetes Mellitus Type 1 / Hypoglycemic Agents / Vascular Stiffness1
4RecruitingTreatmentDiastolic Dysfunction / Type 2 Diabetes Mellitus1
4RecruitingTreatmentFrailty / Obese experiencing rapid weight loss / Sarcopenia / Type 2 Diabetes Mellitus1
4RecruitingTreatmentKidney Transplant; Complications / New Onset Diabetes After Transplant1
4RecruitingTreatmentNAFLD / Type2 Diabetes1
4RecruitingTreatmentNocturnal Hypertension / Type 2 Diabetes Mellitus1
4RecruitingTreatmentNon-Alcoholic Fatty Liver Disease (NAFLD) / Type 2 Diabetes Mellitus1
4RecruitingTreatmentType 2 Diabetes Mellitus2
4RecruitingTreatmentType II Diabetes in Subjects BMI 27 to 32 / Type II Diabetes in the Not so Obese1
4RecruitingTreatmentType2 Diabetes2
4TerminatedTreatmentType 2 Diabetes Mellitus1
4WithdrawnTreatmentAdvanced Glycation End Products / Diabetes Mellitus (DM) / SGLT-2 Inhibitors1
4WithdrawnTreatmentDiabetic Nephropathy Type 21
Not AvailableActive Not RecruitingNot AvailableType 2 Diabetes Mellitus4
Not AvailableActive Not RecruitingBasic ScienceType 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableCardiovascular Disease (CVD) / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableType 2 Diabetes Mellitus2
Not AvailableCompletedDiagnosticLate Dumping Syndrome / Post-gastrointestinal bypass surgery / Postprandial Hypoglycemia1
Not AvailableCompletedTreatmentNon Alcoholic Fatty Liver Diseases (NAFLD)1
Not AvailableNot Yet RecruitingNot AvailableType 2 Diabetes Mellitus1
Not AvailableNot Yet RecruitingTreatmentReperfusion Injury, Myocardial1
Not AvailableRecruitingNot AvailableType 2 Diabetes Mellitus1
Not AvailableRecruitingTreatmentType 2 Diabetes Mellitus1
Not AvailableRecruitingTreatmentType1diabetes1
Not AvailableRecruitingTreatmentType2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, film coatedOral
TabletOral10 mg
TabletOral25 mg
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral25 mg/1
TabletOral
Tablet, extended releaseOral
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
USUS7579449No2005-03-152025-03-15Us
USUS7713938No2006-04-192026-04-19Us
USWO 201416191No2014-04-032034-04-03Us
US7407955No2003-08-122023-08-12Us
US6488962No2000-06-202020-06-20Us
US6303661No1997-04-242017-04-24Us
US6890898No1999-02-022019-02-02Us
US7078381No1999-02-022019-02-02Us
US7459428No1999-02-022019-02-02Us
US8119648No2003-08-122023-08-12Us
US8178541No2003-08-122023-08-12Us
US8846695No2010-06-042030-06-04Us
US9173859No2007-05-042027-05-04Us
US8673927No2007-05-042027-05-04Us
US8883805No2005-11-262025-11-26Us
US8551957No2009-10-192029-10-19Us
US7713938No2007-04-152027-04-15Us
US7579449No2005-11-052025-11-05Us
US9949998No2014-06-112034-06-11Us
US9949997No2014-05-172034-05-17Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.111 mg/mLALOGPS
logP1.79ALOGPS
logP1.66ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)12.57ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area108.61 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity113.79 m3·mol-1ChemAxon
Polarizability45.24 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenolic glycosides. These are organic compounds containing a phenolic structure attached to a glycosyl moiety. Some examples of phenolic structures include lignans, and flavonoids. Among the sugar units found in natural glycosides are D-glucose, L-Fructose, and L rhamnose.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Phenolic glycosides
Alternative Parents
Diphenylmethanes / C-glycosyl compounds / Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / Chlorobenzenes / Aryl chlorides / Oxanes / Monosaccharides / Tetrahydrofurans
show 7 more
Substituents
Phenolic glycoside / Diphenylmethane / C-glycosyl compound / Phenoxy compound / Phenol ether / Alkyl aryl ether / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide
show 17 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
aromatic ether, monochlorobenzenes, C-glycosyl compound, tetrahydrofuryl ether (CHEBI:82720)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
Inhibitor
General Function
Low-affinity glucose:sodium symporter activity
Specific Function
Sodium-dependent glucose transporter. Has a Na(+) to glucose coupling ratio of 1:1.Efficient substrate transport in mammalian kidney is provided by the concerted action of a low affinity high capac...
Gene Name
SLC5A2
Uniprot ID
P31639
Uniprot Name
Sodium/glucose cotransporter 2
Molecular Weight
72895.995 Da
References
  1. Vivian EM: Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents. Drugs Context. 2014 Dec 19;3:212264. doi: 10.7573/dic.212264. eCollection 2014. [PubMed:25598831]

Drug created on March 31, 2015 20:20 / Updated on November 12, 2018 07:34